CALR and essential thrombocythemia: They also noted that ET patients harboring mutations in the JAK2 gene had inferior progression-free survival (PFS) regardless of the presence of a mutation in CALR. They also suggested that response to therapy was superior in patients bearing JAK2 mutations as compared to patients with CALR mutations [16].